Literature DB >> 3495190

Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy.

C Wanke, C U Tuazon, A Kovacs, T Dina, D O Davis, N Barton, D Katz, M Lunde, C Levy, F K Conley.   

Abstract

Although Toxoplasma gondii is the most commonly recognized cause of central nervous system mass lesions in patients with acquired immune deficiency syndrome, published investigations have provided little information about criteria for diagnosis of toxoplasmosis or the response to therapy. In this series the method of diagnosis and response to therapy were assessed in 14 patients who had evidence for toxoplasmosis based on routine histopathology, immunoperoxidase staining, or mouse inoculation. These patients presented with clinical and radiologic findings that did not clearly distinguish them from patients with other infectious or neoplastic processes. Excisional biopsies usually showed tachyzoites on routine histology, but needle biopsies were usually negative unless mouse inoculation or immunoperoxidase staining was employed. Response to pyrimethamine and sulfadiazine therapy was often prompt, but therapy had to be continued for long periods of time to maintain a clinical response, and no alternative regimen of one or more drugs appeared to be effective in patients unable to tolerate both pyrimethamine and sulfadiazine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495190     DOI: 10.4269/ajtmh.1987.36.509

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  24 in total

1.  A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.

Authors:  J A de Diego; P Penin; J R Arribas; E Vázquez; J J Vázquez
Journal:  Folia Microbiol (Praha)       Date:  1996       Impact factor: 2.099

2.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

3.  Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection.

Authors:  M A Jacobson; C L Besch; C Child; R Hafner; K Muth; L Deyton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

4.  Protease activity of 80 kDa protein secreted from the apicomplexan parasite Toxoplasma gondii.

Authors:  Kyoung-Ju Song; Ho-Woo Nam
Journal:  Korean J Parasitol       Date:  2003-09       Impact factor: 1.341

5.  Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures.

Authors:  D S Lindsay; B L Blagburn; J E Hall; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 6.  ABC of AIDS: treatment of infections and antiviral agents.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-12

7.  Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.

Authors:  J A Kovacs; C J Allegra; J C Swan; J C Drake; J E Parrillo; B A Chabner; H Masur
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 8.  Current problems in the management of AIDS patients.

Authors:  N Clumeck; P Hermans; S De Wit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

9.  Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group.

Authors:  D Torre; S Casari; F Speranza; A Donisi; G Gregis; A Poggio; S Ranieri; A Orani; G Angarano; F Chiodo; G Fiori; G Carosi
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 10.  Management of infectious and immunological complications of acquired immunodeficiency syndrome (AIDS). Current and future prospects.

Authors:  C U Tuazon; A M Labriola
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.